Colistimethate Sodium For Injection Ip 1miu/2miu/3miu &4.5miu Dry Powder Injections Vial

What is Colistimethate Sodium For Injection IP 1miu/2miu/3miu &4.5miu Dry Powder Injections Vial?

Colistimethate sodium is an antibacterial medicine belonging to the polymyxin group. It is a prodrug of colistin and is used for selected serious infections caused by susceptible Gram-negative bacteria. The product is supplied as a dry powder injection presentation. Its approved indications, administration route, preparation requirements and strength expression must be confirmed against the product-specific prescribing information.

Uses / Indications

Colistimethate sodium may be used for selected serious infections caused by susceptible Gram-negative bacteria, particularly when treatment options are limited or other suitable antibiotics are ineffective or inappropriate.

Potential clinical applications, depending on the approved product information and susceptibility results, include certain infections associated with organisms such as:

• Pseudomonas aeruginosa

• Klebsiella pneumoniae

• Escherichia coli

• Certain other susceptible Gram-negative bacilli

These examples are not a universal list of approved indications. Treatment selection must consider susceptibility testing, infection site, patient factors and applicable local prescribing guidance.

6. Benefits

• Established antibacterial action: Colistimethate sodium provides colistin activity against susceptible bacteria.

• Dry powder presentation: Supplied in a vial for preparation according to the approved product instructions.

• Multiple stated strengths: The supplied product range lists 1 MIU, 2 MIU, 3 MIU and 4.5 MIU presentations.

• Specialist treatment option: May have a role in selected serious Gram-negative infections when clinically appropriate.

• B2B sourcing enquiries: Kelar Pharmachem India supports pharmaceutical sourcing and export enquiries, subject to confirmation of availability and destination-market requirements.

The medicine has important renal and neurological safety risks and should be used only when clinically justified.

7. Side Effects

Common or recognised adverse effects

Reported adverse effects of colistimethate sodium include:

• Kidney-function abnormalities.

• Tingling or altered sensation.

• Dizziness or other neurological symptoms.

• Muscle weakness.

• Reactions associated with the injection or infusion.

The frequency and severity depend on the patient, dose exposure, renal function and other clinical factors.

Less common or serious side effects

Important risks include:

• Nephrotoxicity: Potentially significant kidney injury.

• Neurotoxicity: Neuromuscular effects, weakness and, in severe cases, respiratory muscle impairment.

• Respiratory depression: Rare but potentially life-threatening neuromuscular toxicity.

• Hypersensitivity reactions: Including serious allergic reactions.

• Electrolyte or other laboratory abnormalities: Where relevant to the patient’s clinical circumstances and product information.

Prompt medical assessment is required if serious adverse effects are suspected. Monitoring of renal function and neurological status may be necessary during treatment.

8. How Does It Work?

Colistimethate sodium is converted in the body to colistin, which acts on the outer and inner membranes of susceptible Gram-negative bacteria. It disrupts bacterial membrane integrity, leading to loss of essential cellular components and bacterial death.

Its activity is limited to susceptible organisms, and resistance can occur. The medicine should therefore be used according to appropriate microbiological evidence, clinical judgement and the approved prescribing information.

9. Dosage Guidelines

Dosage must be determined by a qualified healthcare professional using the approved product information. Relevant factors include:

• The infection and its severity.

• The susceptibility of the causative organism.

• Patient age, body weight and clinical condition.

• Renal function and any need for dose adjustment.

• The strength expression and dosing units used by the specific product.

Important: MIU presentations must not be converted to milligrams or colistin base activity without verified product-specific information. Colistimethate sodium and colistin base activity are different ways of expressing the medicine’s quantity.

Do not infer a dose, frequency, treatment duration, reconstitution volume, diluent, infusion rate or administration route from the vial strength alone. Preparation and administration must follow the approved product label and be performed by appropriately qualified healthcare professionals.

10. When Not to Use

The product should not be used in the following circumstances unless the approved prescribing information and a qualified clinician’s assessment support its use:

• Known hypersensitivity to colistimethate sodium, colistin or relevant product ingredients.

• Infections for which the causative organism is not susceptible.

• Situations where the product is not indicated or an alternative treatment is more appropriate.

• Any product-specific contraindication stated in the approved label.

Renal impairment, neuromuscular conditions and concurrent medicines that may increase toxicity require careful assessment. These may be precautions rather than absolute contraindications, depending on the specific product and patient.

11. Drug / Product Interactions

Clinically relevant interaction concerns may include:

• Nephrotoxic medicines: Concurrent use with medicines that can damage the kidneys may increase the need for renal monitoring.

• Neuromuscular-blocking medicines: Potentially increased concern about neuromuscular weakness or respiratory impairment.

• Other antibiotics: The appropriateness of combination treatment depends on the infection, susceptibility results and clinical guidance.

• Injectable medicines and infusion solutions: Physical compatibility must be established from product-specific documentation.

Healthcare professionals should review all current medicines and assess the potential for additive toxicity. Do not mix colistimethate sodium with another injectable product unless compatibility is confirmed for the exact formulation and preparation conditions.

12. Safety Advice

• Use only under qualified medical supervision.

• Verify the product name, strength, batch number and expiry date before use.

• Confirm the strength expression and dosing units before calculating or administering a dose.

• Assess renal function and relevant neurological risks before and during treatment.

• Review the patient’s allergy history and current medicines.

• Follow the approved preparation and administration instructions.

• Monitor for muscle weakness, breathing difficulties, reduced urine output or other significant adverse effects.

• Do not use the product for self-medication or unsupervised administration.

• Apply appropriate antimicrobial stewardship principles.

13. General Instructions

• Inspect the vial and packaging for damage before preparation.

• Read the approved label and package insert.

• Confirm the specified diluent, reconstitution procedure and intended route.

• Use appropriate aseptic preparation techniques.

• Do not assume compatibility with other medicines or infusion fluids.

• Inspect the prepared solution according to the manufacturer’s acceptance criteria.

• Follow the approved instructions for use after reconstitution or dilution.

• Dispose of unused medicine and preparation materials according to applicable procedures.

Reconstitution volumes, solution concentrations, compatibility and post-preparation stability must be confirmed from the specific manufacturer’s documentation.

14. Special Dietary / Lifestyle Tips

No specific dietary regimen can be recommended from the supplied product details alone.

• Attend recommended clinical and laboratory follow-up.

• Inform the healthcare professional about all medicines and supplements being used.

• Follow advice about hydration and fluid intake based on individual kidney function and clinical condition.

• Report changes in urine output, muscle weakness, tingling or breathing difficulties promptly.

• Do not alter or discontinue treatment without medical advice.

15. Comparison with Other Treatments

These medicines are not automatically interchangeable. Antibiotic selection should be based on the causative organism, susceptibility data, infection site, patient-specific risks and applicable clinical guidance.

16. Precautions & Warnings

• Renal impairment: Kidney function requires careful assessment because colistimethate sodium can cause nephrotoxicity and may require dose adjustment.

• Neurological effects: Monitor for altered sensation, weakness and other signs of neurotoxicity.

• Respiratory risk: Neuromuscular toxicity may impair breathing in severe cases.

• Concurrent medicines: Review medicines associated with renal injury or neuromuscular blockade.

• Strength interpretation: Confirm whether the labelled quantity refers to MIU of colistimethate sodium or another stated activity measure.

• Antimicrobial resistance: Use only when clinically justified and in accordance with appropriate prescribing guidance.

• Pregnancy, breastfeeding and paediatric use: Require assessment against the specific approved product information and the patient’s circumstances.

17. Can I Use It With Other Medicines or Antibiotics?

Use with other medicines or antibiotics requires professional assessment.

The healthcare professional should review the patient’s medicines, renal function, potential neurological risks and the reason for combination treatment. Compatibility with infusion fluids or other injectable medicines must be established separately from clinical interaction risks.

Do not combine, mix or co-administer injectable products without appropriate product-specific compatibility evidence and professional guidance.

18. Storage

Store according to the manufacturer’s approved product labelling. Refer to the product packaging or package insert for the applicable storage conditions.

The storage temperature, light-protection requirements, shelf life and stability after reconstitution or dilution have not been supplied for this specific 1 MIU/2 MIU/3 MIU/4.5 MIU product range. Confirm these details before publication. Storage instructions from another manufacturer’s formulation must not automatically be applied to this product.

19. Frequently Asked Questions (FAQs)

1. What is Colistimethate Sodium For Injection used for?

It may be used to treat selected serious infections caused by susceptible Gram-negative bacteria. The approved indications depend on the specific product and applicable prescribing guidance.

2. What strengths are listed for this product?

The supplied product name lists 1 MIU, 2 MIU, 3 MIU and 4.5 MIU. The precise strength expression should be verified against the approved label.

3. Is colistimethate sodium a cephalosporin?

No. Colistimethate sodium belongs to the polymyxin group of antibiotics and is a prodrug of colistin.

4. Which route of administration is approved?

The route must be confirmed from the approved product information for the specific presentation. Do not assume that all products or formulations have identical administration instructions.

5. How should the powder be reconstituted?

Use only the specified diluent and preparation method in the approved product documentation. Reconstitution volumes and preparation instructions have not been supplied for this product range.

6. What are the major safety concerns?

Important concerns include kidney injury and neurological or neuromuscular toxicity. Treatment requires appropriate medical supervision and monitoring.

7. How should the product be stored?

Follow the manufacturer’s approved labelling. Storage conditions and stability after reconstitution must be confirmed from the product-specific package insert.

8. Is the product available for pharmaceutical export?

Availability, packing options, order quantities and destination-market documentation should be confirmed with Kelar Pharmachem India. No particular export approval or certification is implied.